

Supplemental Figure 4. Analysis of purified Thioredoxin fusions and EMSA competitions.

Monoclonal IgG antibodies raised against the TRX were used in western blotting to immunodetect His-Patch-TRX fusions. **A)** TRX (12 KDa), partial version of BGRF1 deleted in the N-terminal DNA binding domain fused to TRX (28 KDa), full length BGRF1 fused to TRX (55 KDa), partial version of BBR deleted in the C-terminal DNA binding domain fused to TRX (42 KDa); full length BBR fused to TRX (52 KDa). **B)** and **C)** 50 mM, 100 mM and 250 mM imidazole elutions of TRX:BEIL1 (80 KDa) and TRX:BERF1 (51KDa). The purified products consisted of polypeptides of different lengths, including full length forms (stars in figure) and translation intermediates. Molecular Weight is indicated as KDalton at the left-hand side. TRX fusions were used in EMSAs to confirm binding to the intron-located enhancer of *Bkn3* and in gel retardation experiments with increasing amount of cold probes to confirm the specificity of KIBPs binding. **D)** *In vitro* interaction between TRX:BGRF1 and fragments 10 and 11. **E)** *In vitro* interaction between TRX:BEIL1 and fragment 41. **F)** *In vitro* interaction between TRX:BERF1 and fragment 51. 100 ng Poly(dI-dC), 100 ng BSA and 30 ng Heparin were used in EMSAs. (-), free probe; (+), probe + 10-30 ng KIBP fused to TRX; 5X, 25X and 50X refer to molar excess of cold probe included in the binding reaction.